ライフサイエンスコーパス: PK

1 PK analyses showed a >3-fold faster absorption with crus

2 PK analysis of selinexor revealed a clinically insignifi

3 PK analysis was performed under fasting and fed states (

4 PK for 400 mg (day 7) showed Cmax 3.07 muM, Tmax 3.0 hou

5 PK of MFG were determined on day 7 by high-performance l

6 PK parameters were markedly improved: a 16.4-times highe

7 PK-PD modeling of tenofovir (TFV) in plasma, female repr

8 PK/PD analyses using MARS identified isoniazid Cmax and

9 PK/PD analyses were performed at 7 time points.

10 PK/PD analysis predicts that minocycline would be expect

11 PKs had significantly higher postoperative refractive co

12 We identified 49 PKs with a significant loss of fitness in vivo in two in

13 transplant (EK: HR 0.30, 95% CI: 0.17-0.52; PK: HR 0.61, 95% CI: 0.42-0.88).

14 One hundred twelve eyes (67 PK, 45 EK) were included in the study.

15 7 countries were included, recording 180 865 PK cases.

16 There were 871 PKs performed and 67 episodes in 52 eyes of culture-posi

17 A PK curve for an approved antibiotic, levofloxacin, was g

18 A PK/pharmacodynamic (PD) model was developed by measuring

19 In addition, a PK/PD method was established in canines to enable precli

20 ties, and in vitro dose-response data into a PK/pharmacodynamic (PD) model to allow for placement of

21 d model of RNA to describe the response of a PK over a range of mechanical forces (fs) and monovalent

22 ed an in vivo preclinical model to perform a PK-PD analysis of systemic TDF PrEP for vaginal HIV acqu

23 nstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluation.

24 olism, excretion, and pharmacokinetics (ADME-PK) properties of new chemical entities are an integral

25 w to initiate and maintain an in silico ADME-PK infrastructure in an industrial setting.

26 efits, caveats, and impact of in silico ADME-PK should serve as a resource for medicinal chemists, co

27 The in vitro ADME-PK properties of the lead molecules were further optimiz

28 CNS drug-like properties and desirable ADME/PK profile.

29 a program lead compound with a suitable ADME/PK profile for therapeutic development.

30 .0% after EK, 2.1% after ALK, and 3.6% after PK (P = 0.036).

31 Only 1 graft failure, after PK, occurred among the 56 patients with keratoconus.

32 ith the 76% (70%-82%) median cell loss after PK by 68 surgeons in the CDS.

33 the Eld group compared with the Ctrl in all PKs and statistically lower at PKs 1 and 3.

34 ce interval [CI], 2.05-5.33; P < 0.001), and PK was more likely to fail compared with endothelial ker

35 Safety assessments and PK sampling were also performed.

36 was dependent on the presence of the CH and PK domains of both pseudokinases.

37 demonstrated a critical role for the CH and PK regions in promoting cell migration and Stat3 activat

38 es (MARS) were used to identify clinical and PK/PD predictors of 2-month culture conversion.

39 in surviving clear grafts for both DSEK and PK.

40 Five-year survival was comparable for EK and PK (93.4% vs 89.7%, HR = 0.89, P = .261).

41 ce in rejection-free survival between EK and PK for FED or PBK.

42 Long-term graft survival after EK and PK is high and comparable despite lower short-term survi

43 t 3 years, ECD did not differ between EK and PK.

44 ion units and platelet reactivity index, and PK by plasma levels of prasugrel's active metabolite.

45 ty vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues

46 taining both proteinase K (PK)-sensitive and PK-resistant PrP(Sc) and samples containing only the PK-

47 ncentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects m

48 Identification of these virulence-associated PKs provides new insights into T. brucei-host interactio

49 e Ctrl in all PKs and statistically lower at PKs 1 and 3.

50 ivo response, and that physiologically based PK models can assist in the prioritization of leading pr

51 efficacy, we generated physiologically based PK models to simulate systemic and gastrointestinal drug

52 ies-species uptake and physiologically-based PK/PD models.

53 age (P = 0.261) or gender (P = 0.78) between PK and DSAEK groups in our predominantly Chinese (76.6%)

54 No relationship was found between PK exposures and 2-month culture conversion using multiv

55 raft failure is a common indication for both PK and KPro implantation.

56 istical models applied previously to the CDS PK data were considered.

57 %) in magnetic cation content at the central PK layers engenders up to a 90% increase in potential fe

58 inhibitors along with the in vivo mouse CNS PK profile of PF-DcpSi (compound 24), one of the analogs

59 Our described PK-PD approach offers a much needed decision making tool

60 gainst Cryptosporidium but display divergent PK properties.

61 DNA-PK was essential for monocyte adhesion to TNF-alpha-trea

62 DNA-PK-deficient quiescent leukemia cells and BRCA/DNA-PK-de

63 Ri induces moderate ssDNA and triggers a DNA-PK and Chk1-mediated backup pathway to suppress origin f

64 Since SAF-A, DNA-PK catalytic subunit (DNA-PKcs), and protein phosphatase

65 on-catalytic function of XRCC4-LIG4, and DNA-PK activity.

66 entified HDAC1/HDAC9 as well as BRD8 and DNA-PK as important regulators of Golgi breakdown mediated b

67 Downregulation of CD133 and DNA-PK by small interfering RNA, or inhibition of PI3K or Ak

68 otherapeutic regimen targeting CD133 and DNA-PK in combination with traditional protocols may increas

69 ions after PhIP treatment, while ATM and DNA-PK inhibition had only marginal effects.

70 Combined TORK and DNA-PK inhibition in vitro resulted in caspase-dependent cel

71 s and how our knowledge of ATM, ATR, and DNA-PK is being translated to benefit human health.

72 CD133 and DNA-PK may increase MDR1 via the phosphatidylinositol-3-kina

73 The results indicate that CD133 and DNA-PK regulate MDR1 through the PI3K- or Akt-NF-kappaB sign

74 on analysis (GEMA) to identify BRCA- and DNA-PK-deficient leukemias either directly, using reverse tr

75 by three related kinases: ATM, ATR, and DNA-PK.

76 pathway independent of p53, ATM, ATR and DNA-PK.

77 lls, but not Paxx(-/-) cells require ATM/DNA-PK kinase activity for end-ligation.

78 oteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63.

79 icient quiescent leukemia cells and BRCA/DNA-PK-deficient proliferating leukemia cells were sensitive

80 sphorylated in response to DNA damage by DNA-PK and/or ATM.

81 CD133, DNA-PK and MDR1 were markedly elevated in these cells.

82 interactome, which includes NONO, Dhx9, DNA-PK and Stau1, further supports the protein's diverse fun

83 naling pathway consisting of histone H4, DNA-PK, RIP1 and IAPs that attenuates ROS-mediated apoptosis

84 The cisplatin-induced DNA-PK activation was suppressed in histone H4 knockdown cel

85 stone H4 knockdown cells, and inhibiting DNA-PK reduced expression of RIP1 and IAPs in cisplatin-trea

86 pendent on DNA-dependent protein kinase (DNA-PK) and Ataxia telangiectasia mutated (ATM) signaling.

87 ugh CD133, DNA-dependent protein kinase (DNA-PK), and MDR1 are elevated in CD133+ GCSCs, the relation

88 (TORK) and DNA-dependent protein kinase (DNA-PK), was evaluated in primary CLL cells in vitro and in

89 tosis when DNA-dependent protein kinase (DNA-PK)-mediated non-homologous end joining is inhibited.

90 t involves DNA-dependent protein kinase (DNA-PK).

91 lized through APLF interactions with Ku, DNA-PK, and X4L4.

92 d DNA-dependent protein kinase-mediated (DNA-PK-mediated) nonhomologous end-joining, whereas DNA repa

93 Chemical inhibition of DNA-PK enabled dissection of the DNA repair profiles into co

94 tment led to enhanced phosphorylation of DNA-PK, a non-homologous end joining repair protein, in Hec-

95 the inhibition of either caspase-3/7 or DNA-PK during mitotic arrest, promotes subsequent cell survi

96 ered protein that binds Ku, Ku/DNA-PKcs (DNA-PK), and X4L4 within an extended flexible NHEJ core comp

97 complex and result in activation of the DNA-PK and ATM kinases, which play key roles in regulating t

98 PNUTS associates with the DNA-PK complex and is required for DNA-PKcs phosphorylation

99 knockdown of Ku80 and inhibition of the DNA-PK enzyme, which are involved in nonhomologous end joini

100 perative glaucoma compared with repeat donor PK.

101 was developed to incorporate absorbed doses, PK properties, and in vitro dose-response data into a PK

102 , an inducer of contact activation, enhances PK activation by FXII-T, and facilitates FXII-T activati

103 We studied 12-hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites

104 a steady-state TCL level, present stable EVL-PK parameters without significant changes in dose or exp

105 5c had an excellent PK profile across species.

106 inical development candidates with excellent PK properties.

107 ology approach, we have extended an existing PK-PD model of tumor growth with a mechanistic model of

108 has been suggested to lead to more favorable PK/PD profiles.

109 ribed compounds of the class, show favorable PK properties, and demonstrate efficacy in an in vivo St

110 ollowing hydrops and complications following PK.

111 ased risk of endothelial rejection following PK.

112 Leading reported indications for PK between 1980 and 2014 were keratoconus (Europe, Austr

113 the hypothesis that reported indications for PK significantly vary between global regions and over ti

114 Indications for PK within 7 global regions were compared using a modifie

115 ally based pharmacokinetic (PBPK) models for PK prediction of Fc-containing biotherapeutics.

116 Compound 33 was selected for PK studies because it displayed balanced affinities for

117 icantly over time while remaining stable for PK.

118 d using a modified classification system for PK indications and analyzed via multivariate regression.

119 y, about 39% of the antibodies evaluated for PKs in cynos have fast nonspecific (or non-target-mediat

120 s surrogate discovery approach needs further PK studies but in the meantime can be used as an intelli

121 med to provide a thorough overview of global PK indications as reported in peer-reviewed manuscripts.

122 and regional differences in reported global PK indications.

123 Compound 52 was shown to have good PK properties in CD-1 mice and high CNS permeability in

124 Subgroup analysis showed that eyes that had PK or EK for failed TPK conducted for Aspergillus kerati

125 1 men, 4 women) provided two evaluable 12-hr PK profiles.

126 cal candidate for COPD, with predicted human PK properties suitable for once daily human dosing.

127 The human PK properties from the Phase I clinical studies of 37 we

128 eam form Trypanosoma brucei lines identified PKs required for proliferation in culture.

129 In the ILLUMENATE PK study (Pharmacokinetic Study of the Stellarex Drug-Co

130 ll density loss was significantly greater in PK compared with DSAEK (60.9% vs. 48.7%; P = 0.007).

131 ere explored with substantial improvement in PK through modifications at the P1 site, while potency g

132 eplication of CSFV was markedly inhibited in PK-15 cells treated with U0126, a specific inhibitor for

133 Our lead molecule is very potent in PK/PD assays and highly efficacious in a mouse collagen-

134 el significantly lowered GLUT2 and increased PK mRNA levels.

135 ith its two main catabolites, the individual PK profiles of all three components could be derived by

136 t the transcriptional level in CSFV-infected PK-15 cells and in various organs of CSFV-infected pigs.

137 ro and in vivo activity profiles and good iv PK properties.

138 ue for samples containing both proteinase K (PK)-sensitive and PK-resistant PrP(Sc) and samples conta

139 leaved by the serine protease, proteinase K (PK).

140 A total of 5115 keratoplasties (PK = 2390; EK = 2725) were identified.

141 1.56; P < 0.001), penetrating keratoplasty (PK) (adjusted HR, 1.12 vs. ALK and 1.10 vs. EK; P < 0.00

142 plasty (DSAEK) and penetrating keratoplasty (PK) for Fuchs endothelial dystrophy (FED) or bullous ker

143 Penetrating keratoplasty (PK) ranks among the oldest and most common kinds of huma

144 ho had undergone a penetrating keratoplasty (PK), endothelial keratoplasty (EK), or deep anterior lam

145 al keratitis after penetrating keratoplasty (PK).

146 ignaling molecules including protein kinase (PK)C and PKD1.

147 r glycolytic ATP-generating pyruvate kinase (PK) directly into the viral replicase complex to boost p

148 ity (dimeric) M2 isoform of pyruvate kinase (PK) over its constitutively active splice variant M1 iso

149 In mammals, pyruvate kinase (PK) plays a key role in regulating the balance between g

150 e PKM1 and PKM2 isoforms of pyruvate kinase (PK), and PKM2 expression is closely linked to embryogene

151 Protein kinases (PKs) are a class of druggable targets in Trypanosoma bru

152 preclinical PK and clinical human microdose PK data are described leading to the discovery of the fi

153 but low plasma and brain exposure in a mouse PK experiment due to short plasma stability; this was ov

154 nt in vitro properties and a promising mouse PK profile, making it suitable for in vivo testing.

155 igit milliliter volumes to generate multiple PK profiles, simultaneously.

156 ther PKM1 or PKM2 differentially affects net PK activity, viability, and cellular ATP levels of the l

157 Nine PKs had a more pronounced growth defect in vivo, than in

158 spectrometer repetition and noncompartmental PKs were analyzed using Phoenix WinNonlin.

159 xponential cell loss trend characteristic of PK.

160 Examination of PK/PD data from the optimization effort has revealed in

161 Generation of PK profiles by use of the device was initially performed

162 al rate regarding the original indication of PK or offending pathogen.

163 The stable knockdown of PK isoforms in A549 cells significantly reduced the cell

164 Altogether, recruitment of PK and local production of ATP within the replication co

165 coneogenesis; however, in vivo regulation of PK flux by gluconeogenic hormones and substrates is poor

166 eovascularization was present at the time of PK in 44.6% of eyes with prior hydrops and 7.6% without

167 splants that had a rejection episode, 50% of PKs (17) and 60% of EKs (15) subsequently failed.

168 12-hour interval of productive infection on PK-15 cells.

169 s no clinically meaningful impact of food on PKs.

170 e pulling experiments have been performed on PKs to decipher the mechanism of programmed ribosomal fr

171 The co-opted PK generates high levels of ATP within the viral replica

172 The ATP generated by the co-opted PK is used to promote the helicase activity of recruited

173 yzed 828 consecutive cases of DSAEK (423) or PK (405) for FED and BK from the Singapore Cornea Transp

174 ties in predicted exposure concentrations or PK behaviors can significantly influence the prioritizat

175 Hence, the overall (PK) profile of compound II was excellent compared with t

176 e HFS-TB model offers the ability to perform PK/PD studies including humanlike drug exposures, to ide

177 to the central three of the five perovskite (PK) layers is presented, which reveals a marked preferen

178 in-host pharmacokinetic and pharmacodynamic (PK/PD) models with mathematical models for the populatio

179 use of this pharmacokinetic-pharmacodynamic (PK-PD) approach we demonstrate that the killing dynamics

180 mechanistic pharmacokinetic-pharmacodynamic (PK-PD) modeling is increasingly used for antimicrobial d

181 and in vivo pharmacokinetic-pharmacodynamic (PK-PD) properties gave a compound with low predicted dos

182 Pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with isavuconazole plasma co

183 Pharmacokinetic/pharmacodynamic (PK/PD) modeling was applied using efficacy in the murine

184 sed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month culture conversi

185 re we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to rationally develop an anti-Wolbachia

186 n, are often displayed in a pharmacokinetic (PK) profile.

187 xposure concentrations, and pharmacokinetic (PK) characteristics provide the foundation for HT risk p

188 ve biophysical analyses and pharmacokinetic (PK) studies in mouse, rat, and monkey further confirmed

189 tuximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor burden.

190 ort of molecules; available pharmacokinetic (PK) data; protein sequences of ADME-related molecular ta

191 g a dynamic one-compartment pharmacokinetic (PK) model.

192 Compound 10 had the desired pharmacokinetic (PK) and pharmacodynamic (PD) profile and demonstrated ma

193 knowledge as to which drug pharmacokinetic (PK) characteristics are key to generate an in vivo respo

194 lable, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the

195 nnosides that show improved pharmacokinetic (PK) properties relative to O-mannosides.

196 t recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older p

197 in avian medicine, limited pharmacokinetic (PK) data in domestic and companion birds are available.

198 st or slow drug metabolism) pharmacokinetic (PK) profiles were generated from RNA sequencing.

199 be due to a relatively poor pharmacokinetic (PK) profile for the molecule.

200 different uptake potential, pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

201 o 2, but with a preclinical pharmacokinetic (PK) profile that was predictive of once-daily dosing.

202 monized in vivo human serum pharmacokinetic (PK) studies to evaluate the potential in vitro-in vivo c

203 target with mucosal tissue pharmacokinetic (PK) data and mathematical modeling to determine the numb

204 red by their unsatisfactory pharmacokinetic (PK) properties along with the rapid development of drug-

205 zed in vitro and by in vivo pharmacokinetic (PK) and pharmacological studies to unveil its potential

206 absorption affecting drug pharmacokinetics (PK) and pharmacodynamics (PD).

207 rocessing: terfenadine for pharmacokinetics (PK) and toxicity; trimethylamine (TMA) as a potentially

208 ellular uptake mechanisms, pharmacokinetics (PK), administration routes and major challenges in FR-ta

209 ys and in vivo using mouse pharmacokinetics (PK).

210 th assessments for safety, pharmacokinetics (PK) and efficacy.

211 nts with ET and assess the pharmacokinetics (PK) and pharmacodynamics (PD) profile of OA.

212 The pharmacokinetics (PK) studies of immunosuppressive drugs in healthy volunt

213 s of safety, tolerability, pharmacokinetics (PK), and by mRNA expression of the p53 target gene pleck

214 First, we examined the pharmacokinetics (PKs) of methylone and its metabolites after subcutaneous

215 We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexo

216 tween drug concentrations (pharmacokinetics [PK]) and protective efficacy (pharmacodynamics [PD]).

217 Plasma PK levels were positively and significantly associated w

218 trated a positive association between plasma PK and progression of internal carotid IMT.

219 howed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a

220 These novel findings implicate plasma PK as a risk factor for vascular disease in type 1 diabe

221 The circulating levels of plasma PK activity were measured in the plasma of 636 subjects

222 s using a general linear model showed plasma PK to be significantly associated with progression of bo

223 T levels were higher in subjects with plasma PK levels in the highest 10th percentile compared with s

224 ercentile compared with subjects with plasma PK levels in the lower 10th percentile (P = 0.048).

225 ious episodes (47.8%) in the first year post-PK and 35 episodes (52.2%) after the first year post-PK.

226 an occur before or after the first year post-PK.

227 5 episodes (52.2%) after the first year post-PK.

228 Potential PK/PD predictors included 0- to 24-hour area under the c

229 d Ca channels, and an acceptable preclinical PK profile.

230 MPS) was devised that correlated preclinical PK results with cLogD, number of rotatable bonds, and nu

231 sign strategies and results from preclinical PK and clinical human microdose PK data are described le

232 The hypothesis that plasma prekallikrein (PK) is a risk factor for the development of vascular com

233 eding the conserved C-terminal pseudokinase (PK) domain.

234 frameshifting and response of a pseudoknot (PK) RNA to force, a number of single-molecule pulling ex

235 tients aged >18 years who underwent a repeat PK or EK following a failed TPK with a follow-up of at l

236 years was 25% (95% CI, 10%-44%) after repeat PK and 30% in the KPro cohort.

237 glaucoma and infection outcomes after repeat PK versus KPro implantation.

238 ing 20/200 or better at 2 years after repeat PK, compared with an 80% (95% CI, 68%-88%) probability w

239 years was 47% (95% CI, 40%-54%) after repeat PK, whereas the probability of retention of the KPro at

240 utcomes can be achieved by performing repeat PK or EK in patients after failed TPK.

241 Articles with data regarding repeat PK published between 1990 and 2014 were identified in Pu

242 The proportion of clear grafts in the repeat PK group, device retention in the KPro group, and the de

243 opulation model allowed describing rituximab PK and calculating rituximab exposure (area under the co

244 metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and rituximab exposure on outcome in pat

245 DX/MS revealed that catalytically active rM1-PK undergoes significant rigidification in the active si

246 me rigidification was seen upon exposing rM1-PK to substrates or products in the absence of turnover.

247 ach using rabbit muscle pyruvate kinase (rM1-PK) which catalyzes the conversion of phosphoenolpyruvat

248 ries exhibited high oral exposures in rodent PK studies and demonstrated significant tumor growth inh

249 e OEP40 channel is slightly cation-selective PK+/PCl- approximately 4:1 and rectifying (i/i congruent

250 loading and clearance portions of a standard PK curve to be generated.

251 In this study, PK parameters and absolute oral bioavailability expresse

252 Doxycycline exhibits superior PK in comparison to minocycline resulting in a 3-fold gr

253 of TER is the template/pseudoknot domain (t/PK) which includes the template, for adding telomeric re

254 omains are combined to generate a model of t/PK.

255 brate TR contains the template/pseudoknot (t/PK) and CR4/5 domains required for telomerase activity i

256 The organization of the t/PK on telomerase reverse transcriptase for medaka and hu

257 e that the architecture for the vertebrate t/PK is conserved from teleost fish to human.

258 Tacrolimus PK was measured by ultraperformance liquid chromatograph

259 r long-term BSCVA and lower astigmatism than PK over 5 years of follow-up.

260 The PK group had a significantly higher number of cases with

261 The PK model was applied to six occupationally exposed ski w

262 of the test molecule at any point along the PK profile within a coefficient of variation of approxim

263 Other objectives were to characterize the PK/pharmacodynamic (PD) relationship, correlate biomarke

264 For the PK study, we found that methylone and MDC peaked early (

265 h strategy identified 17 128 articles in the PK analysis.

266 gained graft clarity after regrafting in the PK group (P < .01) but not in the EK group (P = .205) at

267 d dehiscence (P = 0.002) were greater in the PK group compared with the DSAEK group.

268 dothelial rejection rates were higher in the PK group.

269 be useful for overcoming limitations in the PK properties of proof-of-concept (POC) compounds to acc

270 ose-dependent effect was demonstrated in the PK/PD model as well as in secondary efficacy outcomes.

271 ce rates and absorbed doses were used in the PK/PD model to evaluate the impact of their uncertaintie

272 overall and 78 isavuconazole patients in the PK/PD modeling.

273 To date, no studies have investigated the PK/PD effects of crushing prasugrel.

274 tant PrP(Sc) and samples containing only the PK-resistant PrP(Sc).

275 Amongst these PKs were several with putative functions related to stre

276 This PK-PD model mimics the human condition and can be applie

277 Also, none of those PK parameters differed statistically when adjusted for b

278 ependent of surgical indication, compared to PK over 5 years.

279 DSAEK was superior to PK over 5 years (P < .001-.026) in FED, but only over 3

280 On the basis of safety, tolerability, PK, and PD, the RP2D was established at 400 mg (15 evalu

281 A total of 245 eyes underwent PK for keratoconus with mean follow-up of 5.6 +/- 3.6 ye

282 Accordingly, a single unified PK/PD model with an effect compartment and sigmoid maxim

283 inted, diffusion-based, and dynamic in vitro PK device.

284 Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouragi

285 a good solubility and an acceptable in vivo PK profile.

286 mparable in vitro potencies, but the in vivo PK properties varied widely.

287 Astigmatism was lower 1 year after EK vs PK (-1.69 vs -3.52 D, P < .001).

288 One-year BCVA was better following EK vs PK (0.34 vs 0.47 logMAR, P < .001).

289 One-year ECD was lower after EK vs PK (1472 vs 1859 cells/mm(2), P < .001).

290 To identify which PK properties are correlated with in vivo efficacy, we g

291 g sickness), yet little is known about which PKs are essential for survival in mammals.

292 In order to assess which PKs are also potential virulence factors essential in vi

293 While PK profiles are determined in animal models, in vitro sy

294 urvival was superior for DSAEK compared with PK (79.4% vs. 66.5%; P < 0.001, log-rank test).

295 urvival following EK was lower compared with PK (94.5% vs 96.3%, HR = 1.56, P = .001).

296 ism, and similar long-term ECD compared with PK for FED and PBK.

297 urvival was superior for DSAEK compared with PK in eyes with FED and BK.

298 ntly decreased with ALK and EK compared with PK.

299 ied 5 and 3 modules of genes correlated with PK parameters and a portion of these were enriched for b

300 K, the 1-year graft survival was higher with PK (90.6%) than with ELK (60.8%) (P = .0025) but no sign